Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Neogenix Oncology files patent application with USPTO for 16C3 antigen

Neogenix Oncology announced today that the company has filed a patent application with the U.S. Patent and Trade Office (USPTO) for the 16C3 antigen. The Company believes that this antigen is tumor specific for pancreatic and colorectal tumors; and, based on preliminary clinical data, may also have diagnostic utility as a biomarker for these cancers.

3 Jul 2010

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has revealed new results from a global survey demonstrating that 66% of patients with metastatic colorectal cancer (mCRC) are now tested for KRAS to determine if they could benefit from a personalized therapy, such as Erbitux® (cetuximab). This represents a 50% increase in levels of KRAS testing in just one year.

1 Jul 2010

Highly specific assay developed to detect ERG alterations in prostate cancer

Researchers at the Uniformed Services University of the Health Sciences Center for Prostate Disease Research, in collaboration with investigators at the Armed Forces Institute of Pathology and Walter Reed Army Medical Center, have developed a highly specific assay for the detection of ERG, a protein associated with tumor formations which is present in more than half of all prostate cancers.

1 Jul 2010

Pre-clinical data of BiTE antibody technology published in PNAS

Micromet, Inc., today announced the publication of pre-clinical data in the Proceedings of the National Academy of Sciences, demonstrating the potency of new product candidates based on the Company's proprietary BiTE antibody technology. BiTE antibodies are a new class of agents designed to harness a patient's T cells to kill cancer cells.

1 Jul 2010

XOMA reaches enrollment goal of 325 patients for Phase 2b clinical trial of XOMA 052

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that it has reached the enrollment goal of 325 patients for its Phase 2b dose-ranging clinical trial of XOMA 052, and that it expects patient enrollment to close in July 2010, with top-line results available in the first quarter of 2011. XOMA 052 is a therapeutic antibody candidate that inhibits the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta) which drives the inflammatory cause of Type 2 diabetes.

1 Jul 2010

USPTO issues Notice of Allowance for patent application related to Neogenix Oncology's 16C3 antibody

Neogenix Oncology announced today that the U.S. Patent and Trade Mark Office has issued a Notice of Allowance for a patent application related to its 16C3 antibody. Discovered and developed by Neogenix Oncology, this antibody appears to have anti-tumor activity for both pancreatic and colorectal tumors, and may have both therapeutic and diagnostic utility. The antibody may have activity in other tumors as well, which the company will explore at such time as it prepares a pre-IND package for FDA review and designs a clinical trial for the 16C3 antibody.

1 Jul 2010

AdVnt launches 15 Minute Black Mold Detection Test

AdVnt Biotechnologies, the company known for producing BioWarfare Agent Detection Devices for HAZMAT First Response Teams around the globe to help them rapidly detect such biological agents as Anthrax, Ricin and Botulinum, has just released its newest product for In-Home and Professional use. Building on the expertise gained in the international arena of BioWarfare Agent Detection, AdVnt is now applying its R&D expertise to help defend against another type of bio threat that could be growing in the walls and under the floorboards in your own home.

30 Jun 2010

Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress

Keryx Biopharmaceuticals, Inc. today announced that abstract O-0017, entitled "Subset Analysis of 5-FU Refractory Patients from a Randomized Ph II Study of Perifosine + Capecitabine (P-CAP) vs. Placebo + Capecitabine (CAP) in Patients with 2nd or 3rd Line Metastatic CRC" has been selected for oral presentation at the upcoming 12th World Congress on Gastrointestinal Cancer, to be held in Barcelona, Spain from June 30 - July 2, 2010.

30 Jun 2010

Zymeworks closes $3.2 million financing round

Zymeworks Inc., a privately held biotechnology company focused on the development of next generation antibody-based therapeutics, today announced the close of a financing totaling $3.2 million. The financing consists of a follow-on round of institutional investment by CTI Life Sciences Fund, L.P. ("CTI") which led the Company's previous financing in 2009.

29 Jun 2010

Pain Therapeutics modifies strategic alliance with King Pharmaceuticals for REMOXY outside U.S.

Pain Therapeutics, Inc. announced today a modification of its strategic alliance with King Pharmaceuticals, Inc. for REMOXY outside the U.S. The move signals a desire to target Europe's small and growing market for strong pain medications.

28 Jun 2010

MorphoSys, Xencor sign worldwide exclusive license, collaboration agreement for XmAb5574 antibody program

MorphoSys AG and US-based biopharmaceutical company Xencor, Inc., announced today the signing of a worldwide exclusive license and collaboration agreement for an antibody in Phase 1 clinical development. The agreement provides MorphoSys with an exclusive worldwide license to XmAb5574, a high potency monoclonal antibody developed by Xencor for the treatment of B-cell malignancies.

28 Jun 2010

Tolerx presents preclinical data on TRX518 anti-GITR immunotherapy for cancer

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, presented results from preclinical studies with TRX518, an early-stage agent Tolerx is developing as a treatment for cancer. TRX518 is a monoclonal antibody to glucocorticoid-induced tumor necrosis factor receptor (GITR) and is designed to enhance the immune system's ability to attack tumors by activating and rendering T effector cells resistant to T regulatory cell suppression.

28 Jun 2010

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, will be presenting new preclinical data in an animal model of Type 2 diabetes in which its anti-inflammatory therapeutic antibody candidate, XOMA 052, was used as monotherapy and in combination with the marketed anti-diabetic drugs exendin-4 (Byetta) or sitagliptin (Januvia).

28 Jun 2010

Additional results from BLISS-76 Phase 3 trial of BENLYSTA presented at International Congress on SLE

Human Genome Sciences, Inc. today announced the presentation of additional results from BLISS-76, one of two pivotal Phase 3 trials of BENLYSTA (belimumab) in seropositive patients with systemic lupus erythematosus. The additional data will be presented in Vancouver at the 9th International Congress on Systemic Lupus Erythematosus on Friday and Saturday, June 25-26.

28 Jun 2010

Overview of scientific research on medical technology to combat anthrax threat

The 2001 anthrax attacks in the United States are fostering development of a new generation of vaccines, antibiotics, and other medications to protect people against the potentially deadly bacteria in any future bioterrorist incident. That's the conclusion of a sweeping overview of scientific research on medical technology to combat the anthrax threat. It appears in ACS' bi-weekly Journal of Medicinal Chemistry.

25 Jun 2010

Patent application for tumor specific NPC-1C Antigen filed by Neogenix Oncology

Neogenix Oncology announced today that it has filed a patent application with the US Patent and Trade Office for the NPC-1C antigen. This antigen appears to be tumor specific for pancreatic and colorectal tumors.

24 Jun 2010

Amorfix Life Sciences, QED Bioscience sign agreement to develop monoclonal antibodies

Amorfix Life Sciences and QED Bioscience announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Under the agreement, QED will generate monoclonal antibodies against several disease specific epitopes on misfolded CD38 protein. The DSE's were identified by Amorfix using their proprietary ProMIS computational platform discovery technology.

24 Jun 2010

Alnylam presents data on novel delivery lipids at IBC 6th Annual Cell Line Development and Engineering conference

Alnylam Biotherapeutics, a division of Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the presentation of new data at the IBC 6th Annual Cell Line Development and Engineering conference held in San Francisco, California from June 21 - 24, 2010.

24 Jun 2010

IQ Therapeutics achieves 100% survival in rabbit model at 48 hours after inhalation anthrax infection

IQ Therapeutics B.V., Groningen, the Netherlands, announced this week that in collaboration with the University of Texas Medical Branch it has obtained outstanding results for the treatment of inhalation anthrax. In a rabbit model up to 100% survival could be achieved with extended time to treatment (48h post infection) with a combination of two specific monoclonal antibodies developed by IQ Therapeutics. This has significant potential for saving lives of infected people who have no immediate access to treatment.

23 Jun 2010

BioWa signs two licensing agreements with GSK

BioWa, Inc. announced today that it has entered into two agreements with GlaxoSmithKline. BioWa and GSK have amended their existing 2007 arrangement in order to provide GSK with extended access to BioWa's POTELLIGENT Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity. The second license agreement provides GSK with access to BioWa's COMPLEGENT Technology for enhancing the complement-dependent cytotoxicity of select GSK therapeutic antibodies.

23 Jun 2010

Monoclonal Antibody News and Research

Further Reading

Neogenix Oncology files patent application with USPTO for 16C3 antigen

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

Highly specific assay developed to detect ERG alterations in prostate cancer

Pre-clinical data of BiTE antibody technology published in PNAS

XOMA reaches enrollment goal of 325 patients for Phase 2b clinical trial of XOMA 052

USPTO issues Notice of Allowance for patent application related to Neogenix Oncology's 16C3 antibody

AdVnt launches 15 Minute Black Mold Detection Test

Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress

Zymeworks closes $3.2 million financing round

Pain Therapeutics modifies strategic alliance with King Pharmaceuticals for REMOXY outside U.S.

MorphoSys, Xencor sign worldwide exclusive license, collaboration agreement for XmAb5574 antibody program

Tolerx presents preclinical data on TRX518 anti-GITR immunotherapy for cancer

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

Additional results from BLISS-76 Phase 3 trial of BENLYSTA presented at International Congress on SLE

Overview of scientific research on medical technology to combat anthrax threat

Patent application for tumor specific NPC-1C Antigen filed by Neogenix Oncology

Amorfix Life Sciences, QED Bioscience sign agreement to develop monoclonal antibodies

Alnylam presents data on novel delivery lipids at IBC 6th Annual Cell Line Development and Engineering conference

IQ Therapeutics achieves 100% survival in rabbit model at 48 hours after inhalation anthrax infection

BioWa signs two licensing agreements with GSK

Monoclonal Antibody Manufacturing Trends eBook eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News